IM Cannabis Corp.

Equities

IMCC

CA44969Q3070

Pharmaceuticals

Market Closed - Canadian Securities Exchange 02:14:58 2024-04-19 pm EDT 5-day change 1st Jan Change
0.84 CAD +5.00% Intraday chart for IM Cannabis Corp. -2.33% +82.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023 MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction. CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months MT
IM Cannabis Announces Receipt of Court Action MT
Transcript : IM Cannabis Corp., Q3 2023 Earnings Call, Nov 13, 2023
IM Cannabis Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IM Cannabis Secures $1.39 Million in Short-Term Debt MT
IM Cannabis Corp. Announces Executive Changes CI
IM Cannabis CFO Steps Down MT
IM Cannabis Corp. Announces Departure of Itay Vago as CFO CI
Transcript : IM Cannabis Corp., Q2 2023 Earnings Call, Aug 14, 2023
IM Cannabis Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
IM Cannabis Brief: Says Received NASDAQ Notification Regarding Minimum Bid Price Deficiency MT
Chart IM Cannabis Corp.
More charts
IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.8 CAD
Average target price
3.45 CAD
Spread / Average Target
+331.25%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. IMCC Stock
  4. News IM Cannabis Corp.
  5. Roth Capital Cuts IM Cannabis Price Target to CA$9.38 From CA$38.59, Maintains Buy Rating